Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on December 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted, 663,000 vest immediately and
Biotechnology, Pharmaceuticals, Health
2025-12-11 8:57 AM EST | Hemostemix Inc.
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for develo
2025-12-11 8:00 AM EST | BetterLife Pharma Inc.
Herbal Dispatch Unveils Strategic Business Plan for 2026 to Drive Sustainable Growth and Enhance Shareholder Value
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leading cannabis e-commerce and distribution platform, today announced its comprehensive Strategic Business Plan for 2026. This plan builds on the Company's robust historical performance, aiming to significantly accelerate revenues while improving gross margins and EBITDA. The plan outlines four key
Pharmaceuticals, Cannabis, Cannabis Dispensary
2025-12-11 3:01 AM EST | Herbal Dispatch Inc.
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce that, further to its news release o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-10 8:00 PM EST | Quantum BioPharma Ltd.
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world's foremost diabetes researchers, to its Scientific Advisory Board. His appointment further enhances TempraMed's scientific foundation as the Company
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-10 5:00 PM EST | TempraMed Technologies Ltd
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce that the Shareholders approved all matters presented at the Company's annual general meeting of the shareholders held today, as follows:
Biotechnology, Pharmaceuticals, Health
2025-12-10 4:30 PM EST | Defence Therapeutics Inc.
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, with ACP
Biotechnology, Pharmaceuticals, Health
2025-12-10 11:17 AM EST | Hemostemix Inc.
Custom Health Announces First Closing of Brokered Private Placement of Subscription Receipts for Gross Proceeds of US$9.6M
Kelowna, British Columbia--(Newsfile Corp. - December 9, 2025) - Custom Health Inc. ("Custom Health" or the "Company"), a vertically integrated, tech-enabled care platform, is pleased to announce that Custom FundCo Inc. ("FundCo") has completed the first closing (the "First Closing") of its previously announced brokered private placement financing of subscription receipts (the "Offering") being conducted in connection with the Company's proposed busin
Technology, Pharmaceuticals, Health
2025-12-09 9:40 AM EST | Custom Health
Telescope Innovations Installs Korea's First Self-Driving Lab for Pharma R&D and Education
HIGHLIGHTS Telescope Innovations' installation of Korea's first Self-Driving Lab for pharmaceutical research completed just three weeks after contract signing Project facilitated by collaboration with the Acceleration Consortium (AC) and supported on site by two-time Chemistry Nobel Laureate Prof. Barry Sharpless Successful SDL delivery demonstrates Telescope's growing commercial momentum, positioning Telescope and the AC to expand SDL adoption across phar
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-09 8:00 AM EST | Telescope Innovations Corp.
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-08 5:00 PM EST | TempraMed Technologies Ltd
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company based in the Netherlands
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-05 5:00 PM EST | TempraMed Technologies Ltd
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee: On-boarding of all new patients entering Hemostemix treatment programs;
Biotechnology, Pharmaceuticals, Health
2025-12-04 9:10 AM EST | Hemostemix Inc.
PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical's proprie
Biotechnology, Pharmaceuticals, Health
2025-12-04 7:00 AM EST | PreveCeutical Medical Inc.
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey. Defence
Biotechnology, Pharmaceuticals, Health
2025-12-04 3:15 AM EST | Defence Therapeutics Inc.
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabetic limb salvage, and regenerative therapeutics gather to present cutting-edge advancements. Hemostemix will highlig
Biotechnology, Pharmaceuticals, Health
2025-12-03 2:05 PM EST | Hemostemix Inc.
BioHarvest Sciences Announces Launch of VINIA Blood Flow Hydration Product
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the U.S. launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow
Biotechnology, Pharmaceuticals, Health
2025-12-03 7:30 AM EST | BioHarvest Sciences Inc.
TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain traction Turkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening compliance One of many distribution agreements in pipeline for Europe as part of TempraMed's def
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-02 5:00 PM EST | TempraMed Technologies Ltd
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company. At closing,
Biotechnology, Pharmaceuticals
2025-12-02 9:53 AM EST | PharmaTher Holdings Ltd.
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists, vascular surgeo
Biotechnology, Pharmaceuticals, Health
2025-12-02 9:10 AM EST | Hemostemix Inc.
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on additional and novel formulations of the KIO-100 family of compounds, This patent allows for additional delivery options, expanding the potential therapeutic utility of the active pharmaceutical ingredient (API) in KIO-104. This newly issued patent specifically covers a novel formulation
Biotechnology, Pharmaceuticals
2025-12-01 6:45 AM EST | Kiora Pharmaceuticals, Inc.